Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp> uchenne muscular dystrophy
Jerry R. Mendell(Nationwide Children's Hospital), Eugenio Mercuri(Università Cattolica del Sacro Cuore), Nathalie Goemans, James Shao(Sarepta Therapeutics (United States)), Linda Lowes(Nationwide Children's Hospital), Katherine Berry(Muscular Dystrophy Association), Edward M. Kaye(Sarepta Therapeutics (United States)), Lindsay N. Alfano(Nationwide Children's Hospital)
Cited by 502
Related Papers
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522